Galapagos NV (GLPG)
|Net Income (ttm)||n/a|
|Day's Range||52.16 - 53.57|
|52-Week Range||46.41 - 72.11|
|Price Target||66.74 (+27.8%)|
|Earnings Date||Aug 4, 2022|
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoart... [Read more...]
In 2021, Galapagos NV's revenue was 484.85 million, an increase of 1.42% compared to the previous year's 478.05 million. Losses were -103.23 million, -66.20% less than in 2020.Financial numbers in EUR Financial Statements
According to 17 analysts, the average rating for GLPG stock is "Buy." The 12-month stock price forecast is 66.74, which is an increase of 27.78% from the latest price.
Mechelen, Belgium; 1 8 August 202 2 , 22 . 01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.
Mechelen, Belgium; 8 August 2022, 22 . 01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC .
Webcast presentation tomorrow , 5 August 202 2 , at 1 4 .00 CET / 8 AM ET, www.glpg.com ,
Here is how Galapagos NV (GLPG) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.
Webcast presentation tomorrow, Wednesday , 22 June 2022 , at 14 .00 CET / 8 AM ET, www.glpg.com
Mechelen, Belgium; 20 June 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.
The consensus price target hints at a 28.3% upside potential for Galapagos NV (GLPG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima...
Here is how Galapagos NV (GLPG) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.
Galapagos In-licenses Novel Drug Targets for Inflammatory Bowel Disease Discovered by Scipher Medicine's Spectra™ Pla...
WALTHAM, Mass.--(BUSINESS WIRE)-- #biotech--Galapagos in-licenses novel drug targets for inflammatory bowel disease (IBD) discovered by Scipher Medicine's Spectra™ Platform.
Here is how Galapagos NV (GLPG) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Here is how Galapagos NV (GLPG) and MedAvail Holdings, Inc. (MDVL) have performed compared to their sector so far this year.
Galapagos NV (GLPG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ...
Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders' meetings
-- Proposal of one-tier board structure & appointment of three new directors -- Mechelen, Belgium; 24 March 2022, 2 1 .01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) published it...
Ryvu Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
KRAKOW, Poland, March 15, 2022 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targ...
Mechelen, Belgium; 03 February 2022, 22 . 01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from EcoR1 Capital , LLC .
Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn's and Colitis Orga...
Mechelen, Belgium; 2 February 2022, 22.01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) will present d ata at the European Crohn's and Colitis Organization (ECCO) annual congress taking place 16-19 Febru...
A high-profile healthcare industry executive has been tapped as the company's new CEO.
Belgian drugmaker Galapagos NV on Wednesday named former Johnson & Johnson senior executive Paul Stoffels as its chief executive officer, effective April 1.
Mechelen, Belgium; 26 January 2022, 22 .40 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its supervisory b oard created 1,000,000 subscription rights under ...
Succeeds current Chief Executive Officer and co-founder Onno van de Stolpe, following planned retirement
Mechelen, Belgium; 6 January 2022, 15.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 40 th A nnual J.P. Morgan Healthcare Conference on January 10-13 , 20 22.
Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
Mechelen, Belgium; 22 November 2021 , 22. 01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) announces completion of recruitment in the MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 i...
Webcast presentation tomorrow , 5 November 202 1 , at 1 3 .00 CET / 8 AM ET, www.glpg.com , +32 2 793 38 47 , code 4987105
Galapagos (GLPG) finishes enrollment in phase III study evaluating filgotinib for Crohn's Disease. The company also assumes sole responsibility for the DIVERSITY study.
Galapagos NV (NASDAQ: GLPG) announced results of two post-hoc analyses from the SELECTION and SELECTION LTE studies of filgotinib for active ulcerative colitis (UC). The analyses showed clinical benefi...